Genomic risk prediction of aromatase inhibitor-related arthralgias (AIA) in breast cancer (BC) patients using a novel analytical algorithm (NAA).
Reinbolt R, Sonis S, Timmers C, Fernández-Martínez J, deAndrés-Galiana E, Hashemi S, Miller K, Ramaswamy B, Wesolowski R, Noonan A, Dewani S, Williams N, Sardesai S, Pilarski R, Lustberg M. Genomic risk prediction of aromatase inhibitor-related arthralgias (AIA) in breast cancer (BC) patients using a novel analytical algorithm (NAA). Journal Of Clinical Oncology 2017, 35: 10102-10102. DOI: 10.1200/jco.2017.35.15_suppl.10102.Peer-Reviewed Original ResearchAromatase inhibitor-related arthralgiaAromatase inhibitorsSystematic chart reviewBreast cancer patientsCase-control studyPeripheral blood cellsAsymptomatic patientsChart reviewTherapy switchTreatment initiationTreatment complianceBC patientsGenomic risk predictionCancer patientsBreast cancerStage IPatientsClinical phenotypeBlood cellsSNP groupGermline DNACandidate gene studiesStrong association